Dermaseq Trademark Details
Word Mark | Dermaseq |
---|---|
Status | Dead 602 — Abandoned-Failure to Respond or Late Response |
Current Owner
Adaptive Biotechnologies Corporation of Seattle, WA
View all trademarks for Adaptive Biotechnologies CorporationSerial Number | 86843003 |
---|---|
Status Date | Tuesday, September 27, 2016 |
Filing Date | Tuesday, September 27, 2016 |
Attorney | Hoang-chi Truong |
Correspondent
HOANG-CHI TRUONG
PATENT LAW WORKS LLP
201 S. MAIN STREET, SUITE 250
SALT LAKE CITY, UT 84111
PATENT LAW WORKS LLP
201 S. MAIN STREET, SUITE 250
SALT LAKE CITY, UT 84111
Case File Statements
Indication of Colors | Color is not claimed as a feature of the mark. |
---|---|
Description of Mark | The mark consists of The mark consists of the word "dermaSEQ," with the term "derma" in lower case and the term "SEQ" in uppercase and the "Q" in "SEQ" is meant to appear as a magnifying glass and has a glint/reflection mark inside the letter. |
Goods & Services | Medical and scientific research in the fields of cutaneous T-cell lymphoma and skin-related cancers and diagnosing and treating same; scientific research, development, engineering, testing, and analytical services for diagnosing and treating cutaneous T-cell lymphoma and skin-related cancers; providing diagnostic assays and diagnostic or prognostic testing for diagnosing cutaneous T-cell lymphoma and skin-related cancers; providing analysis, evaluation, and clinical reports of a patient's condition with regard to cutaneous T-cell lymphoma and skin-related cancers; providing diagnostic assays and diagnostic or prognostic testing for cutaneous T-cell lymphoma and skin-related cancers, and the analysis, evaluation, and reports of those test results to help healthcare professionals determine a patient's diagnosis, prognosis or treatment, to assess the effectiveness of patient treatments, and to revise future treatments accordingly; research and development of diagnostic test kits for detecting and diagnosing cutaneous T-cell lymphoma and skin-related cancers; laboratory research and testing services relating to detecting and diagnosing cutaneous T-cell lymphoma and skin-related cancers; computer services, namely, software as a service (SAAS) services featuring software that provides information, test results for detecting and diagnosing cutaneous T-cell lymphoma and skin-related cancers, and the analysis, evaluation, and reporting of those test results to healthcare professionals to determine a patient's clinical diagnosis, prognosis or treatment, to assess the effectiveness of patient treatments, and to revise future treatments accordingly |
Goods & Services | Medical services; medical analysis and diagnostic services; medical diagnostic services, namely, medical testing for diagnostic or treatment purposes; medical diagnostic services, namely, medical diagnostic testing, monitoring and reporting services; providing medical diagnostic testing for the detection, diagnosis, and treatment of cutaneous T-cell lymphoma and skin-related cancers; providing medical testing for immune responses to immunotherapy or cancer treatment |
Pseudo Mark | Derma Seq |
Classifications
International Class Codes |
042
|
---|---|
U.S. Class Codes | 100, 101 |
Status | 6 — Active |
Status Date | Friday, December 11, 2015 |
Primary Code | 042 |
International Class Codes |
044
|
---|---|
U.S. Class Codes | 100, 101 |
Status | 6 — Active |
Status Date | Friday, December 11, 2015 |
Primary Code | 044 |
Trademark Timeline
-
Dec 08 2015Trademark application filed with USPTO
-
Dec 11 2015New Application Office Supplied Data Entered In Tram
-
Dec 11 2015New Application Entered In Tram
-
Dec 12 2015Notice of Design Search Code and Pseudo Mark E-Mailed
-
Mar 24 2016Assigned To Examiner
-
Mar 25 2016Notification of Non-Final Action E-Mailed
-
Mar 25 2016Non-Final Action E-Mailed
-
Mar 25 2016Non-Final Action Written
-
Sep 27 2016Abandonment Notice Mailed - Failure To Respond
-
Sep 27 2016Abandonment - Failure To Respond Or Late Response